Two previous studies indicated that MCM6 was involved in immune progression dysregulation and might be a target for immunotherapy for systemic lupus erythematosus (58) and anaplastic oligodendroglioma (59). The gene discussed is MCM6; the disease is anaplastic oligodendroglioma.